NCT05575843 (SMARTCARE) is a NA clinical trial of Neurostatus-SMARTCARE in Multiple Sclerosis (MS), sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT05575843?

NCT05575843 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT05575843?

Interventions in NCT05575843: Neurostatus-SMARTCARE, Standard Neurostatus-EDSS.

What condition does NCT05575843 study?

NCT05575843 studies Multiple Sclerosis (MS).

Is NCT05575843 still recruiting?

NCT05575843 is currently completed. Last updated 23 July 2024.

Last reviewed 2024-07-23 · How we verify

NCT05575843: SMARTCARE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®

Completed NA Last updated 23 July 2024

What this trial tests

NA trial testing Neurostatus-SMARTCARE in Multiple Sclerosis (MS) in 101 participants. Completed in 1 March 2024.

Timeline

9 December 2022

Primary endpoint
17 November 2023

1 March 2024

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	other
Enrollment	101
Start date	9 December 2022
Primary completion	17 November 2023
Estimated completion	1 March 2024
Sites	2 locations across Switzerland

Drugs / interventions tested

Neurostatus-SMARTCARE
Standard Neurostatus-EDSS

Conditions studied

Multiple Sclerosis (MS) — all drugs for Multiple Sclerosis (MS) →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Multiple Sclerosis (MS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Expanded Disability Status Scale (EDSS) is the gold-standard in assessing disability in Multiple Sclerosis (MS). Its current digital form, the Neurostatus-eEDSS®, often serves as primary endpoint in MS clinical trials. The pandemic revealed the need for telemedical alternatives to the in-clinic assessment. Therefore, Neurostatus-SMARTCARE was developed: A trained and certified non-neurologist Health Care Professional (HCP) examines the patient while the examination is being video-recorded. The stored video allows a neurologist to re-assess the examination at a later point of time. The future application could be in-home visits through HCPs, in decentralized clinical trials as well as in routine care. In this study, the concordance rate of Neurostatus examinations between neurologists and HCPs is investigated. With a concordance rate significantly higher than 80%, Neurostatus-SMARTCARE by HCPs can be considered equal to the standard Neurostatus-EDSS by neurologists.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.
Mallucci G, Zimmer A, Sfikas N, Cerdá-Fuertes N, et al · · 2025 · cited 2× · PMID 39704409 · DOI 10.1177/13524585241305966

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis (MS)

Currently open trials in the same condition.

NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media · Phase 1 · recruiting
NCT06869278 — A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases · Phase 1 · recruiting
NCT06053749 — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimest · active not recruiting
NCT06270641 — Increasing Physical Activity for Adults With Multiple Sclerosis (MS) · NA · recruiting
NCT06157086 — Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France · active not recruiting

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05575843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 23 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05575843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing